Physician profile
Nicolas Llorens
NPI 1174575294
$8,594.12
in general payments reported to CMS, 2019-2025
38 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $374 · 2021: $933 · 2022: $1,468 · 2023: $1,745 · 2024: $1,830 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,858 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,858.29 |
| Education | $168.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,434.25 | 2019-2025 | |
| Janssen Biotech, INC. | $2,102.82 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $448.71 | 2019-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $332.80 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $304.21 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $272.06 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.52 | 2022-2025 | Trulance, Xifaxan, Plenvu |
| Pfizer INC. | $180.19 | 2019-2024 | |
| Allergan, INC. | $177.06 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $173.64 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $150.50 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $145.29 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $138.54 | 2021-2023 | Ocaliva |
| Celltrion USA INC. | $135.32 | 2024-2025 | Vegzelma |
| Amgen INC. | $129.79 | 2021-2023 | Amjevita, Avsola |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $111.08 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $110.01 | 2020-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $104.85 | 2023-2025 | Zenpep |
| Lilly USA, LLC | $103.91 | 2023-2025 | Omvoh |
| Cook Medical LLC | $100.90 | 2019 | |
| Medtronic, INC. | $87.92 | 2021 | |
| Ironwood Pharmaceuticals, INC | $82.86 | 2021-2024 | |
| Genzyme Corporation | $71.71 | 2023-2025 | |
| Madrigal Pharmaceuticals | $48.80 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $47.34 | 2023-2024 | Rebyota |
| Ardelyx, INC. | $46.85 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $46.85 | 2019-2023 | Injectafer |
| Organon LLC | $40.22 | 2022-2024 | |
| Ucb, INC. | $35.93 | 2019 | |
| Fresenius Kabi USA, LLC | $34.29 | 2023 | Idacio, Smoflipid |
| Ethicon US, LLC | $26.87 | 2023 | Linx Reflux Management System |
| Pharmacosmos Therapeutics INC. | $24.76 | 2022 | |
| Pentax of America, INC. | $24.34 | 2020 | |
| Glaxosmithkline, LLC. | $13.43 | 2022 | |
| Sandoz INC. | $13.39 | 2023 | Hyrimoz |
| Alfasigma USA, INC. | $13.02 | 2022 | |
| Dova Pharmaceuticals | $12.08 | 2019 | |
| Medtronic USA, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Llorens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.